No data to show
XNAS
BRNS
Market cap38mUSD
Jun 10, Last price
1.00USD
Name
Vaccitech PLC
Chart & Performance
P/E
—
P/S
2.58
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
15m
-66.51%
Net income
-61m
L
CFO
-29m
L+100.54%
Profile
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 14,969 | 44,703 16,580.22% | |||
Cost of revenue | 67,923 | 89,854 | |||
Unusual Expense (Income) | |||||
NOPBT | (52,954) | (45,151) | |||
NOPBT Margin | |||||
Operating Taxes | (153) | (4,471) | |||
Tax Rate | |||||
NOPAT | (52,801) | (40,680) | |||
Net income | (61,074) | 5,342 -110.45% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 2,163 | 484 | |||
BB yield | -4.55% | -0.54% | |||
| Debt | |||||
Debt current | 1,920 | 433 | |||
Long-term debt | 22,094 | 17,113 | |||
Deferred revenue | |||||
Other long-term liabilities | 4,010 | 2,676 | |||
Net debt | (86,648) | (176,839) | |||
| Cash flow | |||||
Cash from operating activities | (28,940) | (14,431) | |||
CAPEX | (892) | (6,138) | |||
Cash from investing activities | (892) | (5,750) | |||
Cash from financing activities | 2,163 | 325 | |||
FCF | (51,916) | ||||
| Balance | |||||
Cash | 110,662 | 194,385 | |||
Long term investments | |||||
Excess cash | 109,914 | 192,150 | |||
Stockholders' equity | (263,425) | (136,397) | |||
Invested Capital | 409,577 | 391,047 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 39,348 | 38,169 | |||
Price | 1.21 | 2.35 -78.85% | |||
Market cap | 47,533 | 89,698 -68.82% | |||
EV | (39,009) | (86,836) | |||
EBITDA | (47,154) | (40,828) | |||
EV/EBITDA | 0.83 | 2.13 | |||
Interest | 53 | 19 | |||
Interest/NOPBT | |||||